Skip to main content
 CHANGE IN VISITATION GUIDELINES: Please read before visiting Rutgers Cancer Institute.

Print this page

COG: AHOD1721 Risk-Based, Response-Adapted, Phase II Open-Label Trial of Nivolumab + Brentuximab Vedotin (N + Bv) for Children, Adolescents, and Young Adults with Relapsed/Refractory (R/R) CD30 + Classic Hodgkin Lymphoma (CHL) after Failure of First-Line Therapy, Followed by Brentuximab + Bendamustine (Bv + B) for Participants with a Suboptimal Response. (CheckMate 744: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation)

1. R1 (Low Risk) Cohort: To describe event-free survival (EFS) rate at 3 years, as assessed by blinded independent central review without BMT.
2. To describe the complete metabolic response (CMR) rate prior to HDCT/ASCT using Lugano 2014 response criteria
3. To describe the toxicity of nivolumab + brentuximab in combination in pediatric and young adult participants with relapsed or refractory classical Hodgkin s lymphoma (cHL) after failure of first-line treatment.
4. To characterize pharmacokinetics (PK) of nivolumab and brentuximab followingcombination therapy

Protocol Number: 111605
Phase: Phase II
Applicable Disease Sites: Hodgkin's Lymphoma
Drugs Involved: BENDAMUSTINE
Opdivo (Nivolumab)
Brentuximab vedotin
Principal Investigator: Richard Drachtman M.D.
Scope: National
Therapies Involved: Chemotherapy multiple agents systemic
Participating Institutions:
  • Rutgers Cancer Institute of New Jersey
Inclusion & Exclusion Criteria

Please note that we have obtained the inclusion and exclusion criteria information from the National Institutes of Health’s clinical trials web site The listed criteria may not necessarily reflect recent amendments to the protocol and the current criteria.

For further information about clinical trials, please contact us at 732-235-7356.